Constellation Brands has filed a patent for cannabinoid derivatives with a specific structural formula, along with pharmaceutical compositions containing them and methods of using these derivatives. The compounds were tested and found to exhibit activity as antagonists for both CB1 and CB2 receptors. GlobalData’s report on Constellation Brands gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Constellation Brands Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s, Constellation Brands's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230286906A1) describes a compound with a specific structural formula. The compound can have various substituents, including hydrogen, halo, alkyl, alkenyl, alkoxyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups. The patent also covers different variations of the compound, including enantiomers, diastereomers, racemates, tautomers, and metabolites, as well as their pharmaceutically acceptable salts, solvates, and hydrates.

The patent claims that the compound and its variations can be used in pharmaceutical compositions. These compositions can include the compound along with a pharmaceutically acceptable excipient, diluent, or carrier. The patent suggests that these compositions can be used to treat diseases associated with cannabinoid receptors in subjects in need. The diseases mentioned include those related to CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TPRV2, PPAR?, or µ-opioid receptors.

Furthermore, the patent claims that the compound and its variations can be used to treat a wide range of diseases. These diseases include acute pain, ADHD/ADD, alcohol use disorder, Alzheimer's, anxiety disorders, arthritis, cancer, depression, fibromyalgia, glaucoma, migraine, multiple sclerosis, obesity, Parkinson's, PTSD, schizophrenia, and many others.

In summary, the patent describes a compound with a specific structural formula and various substituents. It suggests that this compound and its variations can be used in pharmaceutical compositions to treat diseases associated with cannabinoid receptors. Additionally, the patent claims that the compound can be used to treat a wide range of diseases, including neurological disorders, psychiatric disorders, pain conditions, and various other ailments.

To know more about GlobalData’s detailed insights on Constellation Brands, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.